Alunbrig (brigatinib)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Alunbrig (brigatinib)

How to buy Alunbrig: You can order Alunbrig (brigatinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer ARIAD Pharmaceuticals
Disease Lung Cancer
Indication ALK-positive NSCLC
Mode of Action ALK inhibitor (targeted therapy)
Approval Status FDA approved (USA)
Strength 30 mg

Who is brigatinib for?

Alunbrig (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who are intolerant to crizotinib, or who experienced the progression of their disease during or after the treatment with crizotinib [1]. Crizotinib is a drug for ALK-positive NSCLC widely approved (e.g. in USA by FDA [2] and in Europe by EMA [3]).

Recommended dose

Complete information about Alunbrig (brigatinib) dosage and administration can be found here: [1].
The standard dosage is:
  • 90 mg orally once daily for the first 7 days;
  • if tolerated, increase to 180 mg orally once daily.
Administer brigatinib until disease progression or unacceptable toxicity. If the dose is not tolerated, the recommended dose reduction levels can be found in the prescribing information: [1].
Consult your treating doctor for personalised dosing.

What is brigatinib and how does it work?

Alunbrig (brigatinib) is a kinase inhibitor used to treat adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who are intolerant to crizotinib, or who experienced the progression of their disease during or after the treatment with crizotinib [1].
The ALK (anaplastic lymphoma kinase) gene plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system [4]. Mutations of the ALK  gene can occur in several different types of cells, including lung cells, and can result in the development of a tumour [2]. ALK gene mutations occur in 3 to 7 % of patients with NSCLC [5].
Patients who have advanced ALK-positive NSCLC are generally highly responsive to ALK inhibitor crizotinib [5][6]. However, almost all patients treated with crizotinib experience progression of their disease, which results in the development of secondary ALK mutations that are resistant to this therapeutics. Approximately 40 % of the ALK-positive NSCLC patients develop metastases in their central nervous system (brain and spinal cord), as an initial site of progression [5][6].
Similarly to crizotinib and alectinib, brigatinib is an ALK-inhibitor, which acts by inhibiting the activity of the ALK protein, and may prevent ALK-positive NSCLC-cells from growing and spreading [7]. Alunbrig (brigatinib) offers an additional option to patients who developed resistance to crizotinib.

What is brigatinib's approval status?

Alunbrig (brigatinib) was approved by:
  • FDA (US) on April 28, 2017
for patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib [7].
The approval was based on a study (ALTA) involving 222 patients with locally advanced or metastatic ALK+ NSCLC who had progressed on crizotinib. The overall response rate was 53 % [95% CI: 43, 62] with 4.5 % complete response rate (as assessed by an Independent Review Committee (IRC)), and the median duration of response was 13.8 months [95 % CI: 5.6, 13.8] as assessed by an IRC. Additionally, 67 % [95 % CI: 41, 87] of patients with measurable brain metastases achieved a confirmed intracranial overall response which lasted about 6 months [7][1].
The most common adverse reactions were nausea, diarrhea, fatigue, cough, and headache [1].
References
[1] Summary of Product Characteristics [FDA]: Alunbrig (brigatinib), ARIAD Pharmaceuticals Inc., Apr. 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf
[2] FDA News Release: FDA approves new oral therapy to treat ALK-positive lung cancer, 11/12/2015.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
[3] EMA. Human Medicines: Xalkori (crizotinib), 14/11/2012 (last update: 13/01/2017), cited on 15/06/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002489/human_med_001592.jsp&mid=WC0b01ac058001d124
[4] Gene Cards. ALK Gene (Protein Coding).
http://www.genecards.org/cgi-bin/carddisp.pl?gene=ALK
[5] Awad M.M. and Shaw A.T.. ALK inhibitors in non–small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul; 12(7):429-39.
https://www.ncbi.nlm.nih.gov/pubmed/25322323
[6] Ou S.H.I., et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol. 2016 Mar; 34(7):661-668.
http://jco.ascopubs.org/content/early/2016/01/07/JCO.2015.63.9443?cmpid=jco_pap_11Jan2016
[7] Drugs.com. FDA Approves Alunbrig, 28/04/2017, cited on 14/06/2017.
https://www.drugs.com/newdrugs/takeda-announces-fda-accelerated-approval-alunbrig-brigatinib-4527.html?utm_source=ddc&utm_medium=email&utm_campaign=Takeda+Announces+FDA+Accelerated+Approval+of+Alunbrig+%28brigatinib%29

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.